176 results about "Bronchial epithelium" patented technology

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The invention discloses an intelligent bronchial endoscope focus detection method, computer equipment and a storage medium. The intelligent bronchial endoscope focus detection method comprises the steps that real, reliable and diversified bronchial endoscope examination images are collected; through data preprocessing, labeling and data division, a bronchial focus detection data set is constructed; an efficient bronchial focus detection network is constructed, and improvement is carried out through multiple attention mechanisms and a convolution module; designing a loss function and training the network to obtain an optimized bronchial focus detection model; and performing focus detection on the acquired image in the real-time bronchoscopy video, and displaying a result. Based on the deep learning technology, the deep neural network model is trained to carry out precise focus type detection on the bronchial endoscope image, real-time bronchial lesion prompt information is provided for endoscope operators, the lesion omission problem during bronchial lesion examination is effectively relieved, the bronchoscopy process is standardized, the endoscope examination quality is improved, and the bronchial lesion detection efficiency is improved. And the workload of operators is reduced.

The invention discloses a bronchial asthma symptom intelligent monitoring method and system based on multi-source data, and relates to the technical field of artificial intelligence, and the method comprises the steps: obtaining multi-mode asthma data after time-space alignment; performing weighted fusion on the western medicine index, the environment index, the tongue condition index and the pulse condition index by using a preset pathogenesis mapping rule to generate an asthma pathology state vector; inputting the asthma pathology state vector into an emergency response channel, analyzing abnormal change of short-term peak flow velocity, synchronously inputting into a chronic evolution channel to track long-term change of tongue condition and pulse condition, and generating emergency response integral and syndrome integral; and superposing the emergency response integral and the syndrome integral on a time axis, and triggering risk assessment when the emergency response integral and the syndrome integral meet the time condition coincidence and the peak flow rate declines to reach an early warning threshold value. According to the method, asthma pathology state vectors are respectively input into an emergency response channel and a chronic evolution channel, so that synchronous monitoring and dynamic modeling of acute attack and chronic disease courses are realized.

The invention relates to a plant astragalus membranaceus-derived exosome-like nano-vesicle as well as a preparation method and application thereof. The nano-vesicle is prepared by chopping astragalus membranaceus roots, juicing, carrying out differential-ultra-high-speed centrifugation and filtering. The nano vesicle disclosed by the invention has good biocompatibility and immunomodulatory activity, can be used for intervening bronchial asthma, and shows a relatively good treatment effect; the nano-vesicle can be used as a novel natural plant-derived drug delivery system, and the problems of poor stability, single action mechanism, low delivery efficiency and the like of traditional Chinese medicine components are solved.

The application discloses a percutaneous lung puncture path planning method and device based on lung segment level blood vessel structure constraint, and the method comprises the following steps: performing isotropic resampling, lung lobe segmentation and bronchial tree extraction on CT image data to generate a three-dimensional lung dissection model; inputting the three-dimensional lung dissection model into a lung segment semantic segmentation module to output a lung segment boundary; reconstructing the topological connection relationship between lung segment level blood supply arteries and drainage veins from the lung segment boundary to obtain a structured lung segment level blood vessel atlas; constructing a dynamic puncture risk field voxel map according to the structured lung segment level blood vessel atlas; sampling a plurality of candidate needle entry points in a surface feasible needle entry region to generate an initial path set in the three-dimensional lung dissection model; and weighting the path length, cumulative risk value, puncture angle penalty and high-density lung tissue volume according to a multi-objective optimization function to output a final puncture path. The application significantly improves the safety boundary and clinical applicability of percutaneous lung puncture.

A method of testing a test substance in an in vitro model of a human tracheobronchial respiratory tract, includes: providing the in vitro model including a cell culture including airway epithelial cells (AECs), a basolateral compartment below the AECs and an apical compartment above the AECs, wherein the AECs form a barrier between the basolateral AND apical compartments; adding the test substance to the apical and / or basolateral compartment; adding a tracer to the basolateral compartment, which is fluorescent, has a molecular weight within 5 kDa of human albumin and is added before, during or after adding the test substance; incubating the cell culture system in a presence of the tracer; collecting at least one sample from the apical compartment; and measuring a fluorescence thereof to determine an effect of the test substance on the AECs. A kit is also disclosed.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The invention belongs to the technical field of biology, and relates to a bronchoalveolar lavage fluid (BALF) preserving fluid, a kit and a cytological test method. The preservation solution is composed of TCEP, N-acetylcysteine, EDTA.2Na, trehalose, Proclin300, methanol, sodium chloride and HEPES, and all the components have a synergistic effect to achieve sample viscosity removal, oxidation resistance, corrosion prevention, cell protection and pH stabilization. The preserving fluid is suitable for morphological observation and nucleic acid detection of BALF cells, and can stably preserve samples at room temperature and maintain completeness of cell membranes and clear morphological structure. The kit comprises two preparations which are mixed to form a working solution, and the working solution can be directly used for sample preservation on a sampling site. The cytological test method comprises the steps of sample collection, preservation, centrifugal slide preparation, Wright-Giemsa staining and microscopic observation. Experimental results show that preservation solutions of different formulas are compatible with a chromosome system, the cell morphology is kept stable within 3 days, the dyeing effect is good, and it is proved that the preservation system can remarkably improve the preservation stability and detection reliability of BALF samples and is suitable for cytology and molecular diagnosis application of lower respiratory diseases.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The present invention provides methods and compositions for the treatment of chronic lung disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1).

The invention provides an atomizing bottle for treating bronchial asthma, and belongs to the technical research field of medical instruments. In order to solve the problem that liquid medicine cannot be effectively sprayed out after being pressed once after an existing dosing device is used for many times, a medicine storage bottle pressurizing mechanism and a to-be-sprayed cylinder are additionally arranged between a medicine spraying pressing rod and a medicine storage bottle; during use, the medicine spraying pressing rod pressurizes the medicine storage bottle for multiple times through the medicine storage bottle pressurizing mechanism while spraying quantitative medicine liquid in the to-be-sprayed barrel from the nozzle, so that enough medicine liquid in the medicine storage bottle is extracted into the to-be-sprayed barrel, and therefore, in emergency medicine application, it can be guaranteed that the enough and quantitative medicine liquid is sprayed out after a patient presses the medicine liquid once.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

The invention discloses a bronchial lung dysplasia severity prediction method and related equipment, and belongs to the technical field of machine learning, and the method comprises the steps: obtaining the clinical data of a target object; preprocessing the clinical data of the target object, constructing a training set and a verification set according to a preset proportion, and screening to obtain a target variable; based on the target variable, constructing a plurality of bronchial lung dysplasia severity prediction models by using the training set, and performing model performance evaluation on the plurality of constructed bronchial lung dysplasia severity prediction models in the verification set; and obtaining a bronchial lung dysplasia severity prediction model with the optimal performance so as to complete bronchial lung dysplasia severity prediction. The clinical data of the target object is combined with the machine learning algorithm, so that the dynamic change of the immune system of the premature infant can be reflected more comprehensively, the prediction accuracy of the severity of early bronchial pulmonary dysplasia is improved, and scientific data support is provided for clinical treatment selection.

The invention discloses a preparation method of a pyridopyrimidine compound and application of the pyridopyrimidine compound in preparation of an asthma medicine. The pyridopyrimidine compound provided by the invention is applied to preparation of medicines for preventing / treating asthma, DPPO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the DPPO can obviously inhibit attack of asthma and secretion of related inflammatory factors such as IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17A, has a relaxation effect on tracheal smooth muscles, has the effects of resisting angiogenesis, airway remodeling and inflammation, and achieves the effect of treating asthma. In addition, current researches show that the asthma pathogenesis is very complex, DPPO can obviously improve pathological changes of mouse lung tissues sensitized by house dust mite extract (HDM) and toluene diisocynate (TDI), and the DPPO has certain universality and can be speculated to have huge application potential in research and development of drugs for treating various asthma.

The invention relates to the technical field of medical image processing, and discloses a chronic obstructive pulmonary emphysema distribution quantitative method and system based on multi-scale segmentation, and the method comprises the steps: carrying out the anisotropic diffusion filtering noise reduction of a chest CT image; segmenting a lung field and removing a blood vessel bronchial structure by adopting a region growing algorithm; multi-scale image representation is constructed based on a Gaussian pyramid, an emphysema candidate area is identified in a coarse scale layer, and a boundary is accurately drawn by adopting a self-adaptive threshold value in a fine scale layer; extracting local texture features to distinguish the lobular central emphysema and the total lobular emphysema; dividing severity levels according to spatial aggregation characteristics and density gradient distribution, and calculating an air swelling volume ratio and a distribution heterogeneity index; the three-dimensional pseudo-color volume is used for drawing visualization, a structured quantitative report is generated, accurate segmentation and subtype classification of the emphysema area are achieved, and comprehensive quantitative analysis indexes are provided.

The invention belongs to the technical field of animal model construction, and particularly relates to a construction method and application of a bronchiectasis animal model. According to the method, the bronchiectasis animal model is constructed in a manner of alternately infecting the animal with the self-separated pseudomonas aeruginosa and injecting the protease into the airway of the animal, so that the stable bronchiectasis animal model is successfully obtained, and the modeling success rate is relatively high. It is confirmed through imaging and pathological detection means that the constructed bronchiectasia animal model meets the diagnostic standard of bronchiectasia, chronic pseudomonas aeruginosa airway infection in bronchiectasia can be accurately simulated, structural changes of bronchiectasia are copied, and auxiliary clinical research and application are facilitated.

The utility model belongs to the field of in-vitro cell culture and exposure, and particularly relates to a cell culture exposure unit, a cell culture exposure device and a bionic breathing type exposure system. The cell culture exposure unit is provided with a microporous membrane, a gas chamber and a liquid chamber, the gas chamber and the liquid chamber are located on the two sides of the microporous membrane respectively, a refining baffle is arranged at the position, close to the microporous membrane, in the liquid chamber, and the refining baffle is provided with a microporous structure used for refining CO2 exhaled by the CO2 exhaling device. And the plate surface of the refining baffle plate faces the microporous membrane within the range of the plate surface. The device can better simulate that CO2 in the body stably and naturally passes through a gas-blood barrier, can adapt to different hierarchical positions and shunt flow of a bronchial tree, and is more objective and real in bionic simulation of inhalation exposure and in-vivo environment, thereby being beneficial to obtaining more real and scientific research results.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The present invention relates to the use of antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, for restoring and / or normalizing epithelial barrier function for treating and / or preventing acute respiratory failure.In particular, antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, is (are) herein disclosed to be of use in counteracting and / or normalizing fluid transfer across epithelial cell barriers with a significant impact on a large proportion of patients with traumatic lung injury, such as but not limited to patients suffering from abnormal accumulation of fluid in the lung alveoli and / or bronchioles selected from the list of patients suffering from BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular lung disorder.

The invention provides a method for synthesizing a seven-membered ring intermediate of a high-purity bronchus drug Bruxocateb. The synthesis method is simple and efficient, the starting materials are cheap and easy to obtain, post-treatment is convenient, and industrial production is easy. The preparation operation of the salt of the key intermediate in the route is simple and convenient, the purification effect on the product is good, and industrial production is facilitated to obtain the high-purity seven-membered ring intermediate of the bruxicapil. .

The invention provides a tumor in-situ pathology detection system based on an endoscopic multi-mode probe. The tumor in-situ pathology detection system comprises a main controller, an SC laser, a DUV laser, a comb filter, a polarizer, a microarray lens, a multiplexing beam combiner, a conjugate coupling module, an endoscopic optical fiber bundle, a FAST optical fiber bundle, an SC spectrograph and a DUV spectrograph. Aiming at G14-level bronchial navigation surgical robot in-situ pathology detection, the invention provides a detection system based on an endoscopic multi-mode optical probe, FAST hyperspectral image spectrum integrated detection of SC, DUVRS, DUVLIF and mIHC can be realized, a multi-mode hyperspectral fusion image reflecting spatial distribution of histochemical components of a diagnosis point and corresponding spectral feature data are output, and the detection system is used for detecting the in-situ pathology of the G14-level bronchial navigation surgical robot. And real-time, accurate and multi-mode data or information is provided for diagnosis of doctors.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The application discloses a bronchial asthma phenotype identification index screening method based on exosomeomics, comprising the following steps: acquiring bronchial asthma medical record data to construct a medical record data subset, and extracting multi-dimensional information to obtain diagnostic characteristics; generating an original feature set by using common diagnostic characteristics of different bronchial asthma phenotypes; constructing a knowledge graph according to exosomeomics related knowledge and the action mechanism of exosomes of different cell sources on bronchial asthma, screening exosome characteristics, and expanding the original feature set; constructing a feature selection task based on multi-objective optimization, obtaining exosome feature combinations of different bronchial asthma on the basis of the common diagnostic characteristics, and determining exosome identification indexes of bronchial asthma phenotypes after comparison and verification of the identification accuracy of the original common diagnostic characteristics. The exosomeomics indexes highly related to bronchial asthma diagnosis are screened, biomarkers are obtained for predicting allergic and asthma conditions, and the identification accuracy of bronchial asthma phenotypes is improved.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The invention discloses a method for detecting mouse bronchial Bordetella by using a qPCR (quantitative polymerase chain reaction) technology instead of a traditional sacrificial sentinel mouse, and a specific primer and probe combination comprises a forward primer sequence: 5 '-CGTTGTCGGCTTTCGTCTG-3', as shown in SEQ ID NO.1; the sequence of a reverse primer is 5 '-ACTATACGTCGGAAATCTGTTTG-3', and the sequence of the reverse primer is as shown in SEQ ID NO. 2; and a probe sequence: 5 '-FAM-CGGGCCGATAGTCAGGGCGTAG-BHQ1-3', and the probe sequence is as shown in SEQ ID NO. 3. The method disclosed by the invention has the beneficial effects that an analysis method suitable for detecting the bronchial Bordetella in the animal cage environment sample is established, the bronchial Bordetella in the environment sample can be rapidly and accurately detected and quantified by the method, and a technical support is provided for pathogen pollution control.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

This disclosure relates to anti-Pseudomonas Psl and PcrV bispecific antibodies for use in treatment of bronchiectasis.

Provided herein are method of treating a patient with nontuberculous mycobacteria by administering nitric oxide to the patient for at least 100 days to increase functional capacity and quality of life of the patient.

The invention provides a bronchial classification method and device, electronic equipment and a storage medium, and the method comprises the steps: carrying out the skeleton extraction of bronchial image data, and generating a bronchial point cloud model; performing node classification identification on nodes in the bronchial point cloud model, and generating a point cloud binary tree according to a node classification identification result; classifying the point cloud binary tree based on the relative position relationship of each node in the point cloud binary tree; and according to a classification result of the point cloud binary tree, performing classification restoration in the bronchial image data to obtain a bronchial classification result. Compared with the prior art, the morphological characteristics of the bronchus can be accurately and effectively extracted through skeleton extraction, so that subsequent analysis and classification are more reliable; nodes in the point cloud model are classified, so that the diagnosis accuracy is improved; by constructing the point cloud binary tree, the bronchus can be represented in a structured mode, and accurate classification of the bronchus in the bronchus image data is realized.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.